VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+5.59%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$169M
AUM Growth
-$13M
(-7.2%)
Cap. Flow
-$16.1M
Cap. Flow
% of AUM
-9.55%
Top 10 Holdings %
Top 10 Hldgs %
6.26%
Holding
495
New
55
Increased
122
Reduced
257
Closed
60
Top Buys
| 1 |
NVIDIA
NVDA
|
$1.21M |
| 2 |
Netflix
NFLX
|
$1.05M |
| 3 |
Meta Platforms (Facebook)
META
|
$1.04M |
| 4 |
Adobe
ADBE
|
$995K |
| 5 |
Applied Materials
AMAT
|
$977K |
Top Sells
| 1 |
ATVI
Activision Blizzard Inc.
ATVI
|
$1.01M |
| 2 |
Progressive
PGR
|
$999K |
| 3 |
Stryker
SYK
|
$984K |
| 4 |
Republic Services
RSG
|
$973K |
| 5 |
Linde
LIN
|
$966K |
Sector Composition
| 1 | Healthcare | 27.98% |
| 2 | Technology | 15.96% |
| 3 | Financials | 11.34% |
| 4 | Energy | 8.43% |
| 5 | Industrials | 8.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
376
Precigen
PGEN
$1.3B
| $101K | 0.06% |
87,692
+28,522
| +48% | +$32.8K |
|
|
IGMS
377
DELISTED
IGM Biosciences
IGMS
| $101K | 0.06% |
10,896
+5,783
| +113% | +$53.4K |
|
378
Kura Oncology
KURA
$713M
| $100K | 0.06% |
9,480
+1,795
| +23% | +$19K |
|
379
Lyell Immunopharma
LYEL
$233M
| $100K | 0.06% |
1,576
+155
| +11% | +$9.86K |
|
380
Cogent Biosciences
COGT
$1.82B
| $100K | 0.06% |
8,462
+95
| +1% | +$1.13K |
|
381
Caribou Biosciences
CRBU
$174M
| $99.8K | 0.06% |
23,486
+11,087
| +89% | +$47.1K |
|
382
Atea Pharmaceuticals
AVIR
$267M
| $99.4K | 0.06% |
26,586
+3,638
| +16% | +$13.6K |
|
383
Cullinan Oncology
CGEM
$413M
| $99.4K | 0.06% |
9,239
+756
| +9% | +$8.14K |
|
384
TG Therapeutics
TGTX
$5.11B
| $99.4K | 0.06% |
4,001
-7,053
| -64% | -$175K |
|
|
PNT
385
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $99.1K | 0.06% |
10,939
-3,963
| -27% | -$35.9K |
|
386
Nurix Therapeutics
NRIX
$758M
| $99K | 0.06% |
9,912
+1,731
| +21% | +$17.3K |
|
387
Avidity Biosciences
RNA
$6.48B
| $98.9K | 0.06% |
8,920
+2,989
| +50% | +$33.1K |
|
388
Denali Therapeutics
DNLI
$2.26B
| $98.8K | 0.06% |
3,349
+56
| +2% | +$1.65K |
|
389
Dyne Therapeutics
DYN
$2.02B
| $98.7K | 0.06% |
8,769
+1,434
| +20% | +$16.1K |
|
390
Krystal Biotech
KRYS
$4.35B
| $98.6K | 0.06% |
840
-466
| -36% | -$54.7K |
|
391
Disc Medicine
IRON
$2.11B
| $98.5K | 0.06% |
+2,219
| New | +$98.5K |
|
392
Xenon Pharmaceuticals
XENE
$3.02B
| $98.3K | 0.06% |
2,552
-58
| -2% | -$2.23K |
|
|
KRTX
393
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $98.2K | 0.06% |
453
-44
| -9% | -$9.54K |
|
394
Celldex Therapeutics
CLDX
$1.52B
| $98.1K | 0.06% |
2,892
+379
| +15% | +$12.9K |
|
395
Intellia Therapeutics
NTLA
$1.29B
| $98.1K | 0.06% |
2,406
-204
| -8% | -$8.32K |
|
396
Madrigal Pharmaceuticals
MDGL
$9.65B
| $97.9K | 0.06% |
424
-1,309
| -76% | -$302K |
|
397
Arcutis Biotherapeutics
ARQT
$2.06B
| $96.9K | 0.06% |
10,172
+4,084
| +67% | +$38.9K |
|
398
Kymera Therapeutics
KYMR
$3.11B
| $96.9K | 0.06% |
4,215
+796
| +23% | +$18.3K |
|
399
Immunovant
IMVT
$2.99B
| $96.9K | 0.06% |
5,107
-1,594
| -24% | -$30.2K |
|
|
ALLK
400
DELISTED
Allakos
ALLK
| $96.8K | 0.06% |
22,191
+7,756
| +54% | +$33.8K |
|